Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 6/20 | 0.63 |
| ▸ | SYK | P43405 | 1/20 | 0.59 |
| ▸ | JAK2 | O60674 | 1/20 | 0.58 |
| ▸ | WEE1 | P30291 | 1/20 | 0.56 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 3/20 | 0.56 |
| ▸ | BRD4 | O60885 | 4/20 | 0.53 |
| ▸ | IGF1R | P08069 | 1/20 | 0.53 |
| ▸ | STAT6 | P42226 | 1/20 | 0.52 |
| ▸ | ULK1 | O75385 | 1/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11916385 | 1.00 | FGFR1 (0.63) | FGFR1SYKJAK2WEE1ALK | |
| SCHEMBL11916311 | 0.87 | FGFR1 (0.51) | FGFR1SYKJAK2WEE1ALK | |
| SCHEMBL11916428 | 0.86 | CCNK (0.65) | SYKALKEGFRBRD4IGF1R | |
| SCHEMBL11919317 | 0.86 | PDGFRB (0.63) | FGFR1SYKJAK2WEE1ALK | |
| SCHEMBL11916309 | 0.85 | FGFR1 (0.51) | FGFR1JAK2WEE1ALKSTAT6 | |
| SCHEMBL19203832 | 0.84 | FGFR1 (0.64) | FGFR1SYKJAK2WEE1ALK | |
| SCHEMBL19203860 | 0.83 | BRD4 (0.55) | FGFR1SYKWEE1ALKEGFR | |
| SCHEMBL11916395 | 0.83 | CHEK1 (0.59) | FGFR1WEE1ALKULK1 | |
| SCHEMBL11916655 | 0.82 | GSK3A (0.67) | FGFR1SYKJAK2EGFRIGF1R | |
| SCHEMBL11916427 | 0.81 | GSK3A (0.66) | FGFR1SYKJAK2EGFRIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200317705-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2020-10-08 | — | — | US | disclosed |
| US-20200048288-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-02-13 | — | — | US | disclosed |
| EP-2300013-B1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMA INC (US) | 2017-09-06 | — | — | EP | disclosed |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-20160376297-A1 | Phosphorous Derivatives as Kinase Inhibitors | ARIAD PHARMA INC (US) | 2016-12-29 | — | — | US | disclosed |
| US-9273077-B2 | Phosphorus derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273077-B2 | Phosphorus derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150225436-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2015-08-13 | — | — | US | disclosed |
| US-20150225436-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2015-08-13 | — | — | US | disclosed |
| US-9012462-B2 | Phosphorous derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-9012462-B2 | Phosphorous derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-20140066406-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140066406-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066406-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | FGFR1 542/4885SYK 525/4885JAK2 361/4885 |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | FGFR1 383/4885SYK 558/4885JAK2 329/4885 |
| US-20150225436-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | FGFR1 411/4885SYK 524/4885JAK2 305/4885 |
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | PHKA1, PIK3CA, PHKA2 | FGFR1 513/4885SYK 572/4885JAK2 406/4885 |
| US-20160376297-A1 | Phosphorous Derivatives as Kinase Inhibitors | MAP3K6, PIK3CA, MAP3K20 | FGFR1 411/4885SYK 524/4885JAK2 305/4885 |
| US-20200317705-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | FGFR1 383/4885SYK 558/4885JAK2 329/4885 |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | FGFR1 542/4885SYK 525/4885JAK2 361/4885 |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | FGFR1 542/4885SYK 525/4885JAK2 361/4885 |
| US-20200048288-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | FGFR1 383/4885SYK 558/4885JAK2 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.